Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy.

Pharmaceutics · 2022 · PMC9505720 · PMID 36145516

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In contrast, KEYNOTE-240, another phase 3 clinical trial, tested the efficacy and safety of pembrolizumab, an anti-PD-1 monoclonal antibody, as monotherapy for advanced HCC, and its result did not reach statistical significance [ 14 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.